Abnormalities in clinical parameters and routine laboratory tests are frequently detected at late stages of many diseases (too late to cure or to prevent life-threatening complications). Hence earlier diagnostic and prognostic markers are needed for decision making and improving therapeutic outcome. In the present issue of Clinical Science, Rudiger and co-workers report findings from a transcriptomic study, which revealed that changes in transcripts involved in amino-sugar metabolism, p53-dependent cell-cycle arrest, β-adrenergic signalling and intracellular calcium cycling in cardiac tissue of rats with early sepsis could discriminate survivors from non-survivors. These findings underscore the great potential of systems biology in translational medicine. However, further investigations should be done to make the benchside results more feasible for routine clinical practice.
Clinical manifestations and abnormal laboratory tests are frequently present at late stages of many diseases. Moreover, such abnormalities are usually unable to predict disease outcome and therapeutic response. Even with appropriate treatment with standard regimens, mortality rates of some severe diseases remain high and life-threatening complications remain common. This urges clinicians and scientists to search for earlier diagnostic and prognostic markers, which will be helpful in decision making and improving therapeutic outcome. Between diagnostic and prognostic markers, defining the latter seems to be more difficult to achieve [1] .
Over the last decade, systems biology has been widely applied to search for prognostic markers in many diseases [2] [3] [4] . A huge number of candidates for prognostic markers have been identified recently in various studies using clinical samples or animal models. However, the major shortcoming of these recent investigations is that most of them have reported only changes or differences between groups, whereas a much smaller number of studies have demonstrated the practicality of those findings in clinical practice [5, 6] . In the present issue of Clinical Science, Rudiger and co-workers [7] report the data obtained from systems biology of early sepsis using a rat model. This is a well-performed study to demonstrate that a reduction in myocardial function and transcriptomic changes at an early phase of sepsis could predict clinical outcome in rats with sepsis.
The investigators first showed that, at 6 h after the induction of sepsis, cardiac stroke volume <0.17 ml could predict Correspondence: Professor Visith Thongboonkerd (e-mail thongboonkerd@dr.com or vthongbo@yahoo.com) the mortality of rats with sepsis with 93 and 80 % positive and negative predictive values respectively [7] . Transcriptomic analysis was subsequently performed to define altered transcripts and their pathways that were related with poor clinical outcome. The findings showed significant alterations in the expression of 527 transcripts in cardiac tissue of rats with sepsis. Some of these changes were related to anaesthesia and instrumentation, not to sepsis itself, whereas only 120 out of the 527 altered transcripts could discriminate survivors from non-survivors. Interestingly, network analysis revealed that the altered transcripts induced by sepsis were involved mainly in inflammatory process, organ injury, musculoskeletal disorder and cardiovascular disease, whereas those related to the poor clinical outcome were involved in amino-sugar metabolism, p53-dependent cell-cycle arrest, β-adrenergic signalling and intracellular calcium cycling [7] . This reflects a benefit from including more than one control group (i.e. naïve and sham groups in the present study) in a training set of transcriptomic screening to increase the 'specificity' of the findings [5, 6] . In addition, it is advisable for any biomarker discovery studies to also include the disease controls (other diseases that mimic clinical and laboratory features of the disease of interest) to increase the feasibility for defining so-called 'diseasespecific' markers.
Overall, the present study by Rudiger et al. [7] serves as a good example of systems biology aiming for clinical applications. However, these findings derived from an animal model should be validated in a large cohort of patients with sepsis to determine their sensitivity and specificity to predict the poor clinical outcome in humans [8] . Moreover, elucidation of functional roles that these altered transcripts play in the mechanistic pathways of severe sepsis should be also performed to search for new therapeutic targets and for a more effective treatment of sepsis (with the ultimate goal to reduce life-threatening complications and mortality rate). It should be noted that selection of the samples for such investigations is a crucial issue. The present study by Rudiger et al. [7] focused on transcriptomic changes only in the cardiac tissue, because they aimed to correlate these changes with cardiac physiological data. As pathophysiological processes in various cells and tissues differ, it is expected that there are 'tissue-specific' alterations in transcriptomic, proteomic and other signatures [9] . This is also true for the present study, in which the investigators have indicated that transcriptomic analysis of concurrently taken liver samples revealed different signalling pathways [7] . Therefore 'tissue-specific' markers should be elucidated, particularly for the diseases in which mechanisms of injury of multiple organs are different. Otherwise, the 'diseasespecific' markers that can be detected in all or most of the tissues must be defined.
Further investigations should be also directed to translating the benchside results to routine clinical practice. Although 'tissuespecific' markers are suitable for determining the specific organ injury, the practicality and their use in routine clinical practice may be limited. In addition, it may be illegal to obtain tissues or cells from the affected organs for monitoring a therapeutic response. Therefore biomarkers in easily accessible body fluids (whole blood, plasma/serum, urine etc.) may be more attractive. However, such markers should have a predictive value and represent the pathophysiology that can be detected at the tissue/organ level. Taking these into account, Taurino et al. [10] have reported previously in Clinical Science another promising transcriptomics study. In that study, mRNA and microRNA expression profiles were examined in whole blood to discover genes that could determine cardiovascular phenotypes in patients with coronary artery disease. Those genes were likely to play pivotal roles in the pathogenic mechanisms and progression of chronic coronary artery disease [10] .
Finally, the selection of the type of body fluid for biomarker discovery needs attention. Changes observed in body fluids are most reliable to the diseases of organs that are closely related to such biofluids (e.g. urine for kidney diseases, pleural fluid for lung diseases, cerebrospinal fluid for brain and spinal cord diseases etc.), because abnormalities in these organs can directly affect secretion/excretion of those markers into the corresponding body fluids. Unlike others, plasma/serum is related to almost all of the organs. However, changes that can be observed in the plasma/serum must reach a threshold of the detectability of an assay to be used. As there is a wide dynamic range of levels of marker molecules in plasma/serum, the low abundant markers may be undetectable. Moreover, the changes observed in plasma/serum are the results of averaged effects from all of the affected organs, thereby reducing the organ specificity. Therefore selection of the samples to be investigated is not simple, but is indeed one of the most sophisticated issues in the study design for biomarker discovery.
In summary, the systems biology approach holds a great promise in translational medicine. However, there are several challenges that need further investigations to make the benchside results more feasible for routine clinical practice. 
